Core Viewpoint - Zhendemedical (603301) has shown significant stock performance with a 10% increase and consecutive trading limit ups, indicating strong market interest and potential investor confidence [1] Financial Performance - For the first three quarters of 2025, Zhendemedical reported a main revenue of 3.184 billion yuan, a year-on-year increase of 1.88% [1] - The net profit attributable to shareholders was 203 million yuan, reflecting a year-on-year decline of 33.91% [1] - The third quarter alone saw a main revenue of 1.084 billion yuan, a slight increase of 0.1% year-on-year, while the net profit for the quarter was 75.42 million yuan, down 48.47% year-on-year [1] - The company’s gross profit margin stands at 33.93% [1] Market Activity - As of February 10, 2026, Zhendemedical's stock closed at 88.76 yuan with a trading volume of 68,000 hands and a total transaction amount of 594 million yuan [1] - The net inflow of main funds was 48.1 million yuan, accounting for 8.1% of the total transaction amount, while retail investors saw a net outflow of 14.32 million yuan [1] - The financing data indicates a net purchase of 84.66 million yuan, ranking 11th in the market [1] Institutional Ratings - In the last 90 days, two institutions have rated Zhendemedical with a buy rating, and the average target price set by these institutions is 101 yuan [2]

Core Viewpoint - The stock of Aojing Medical (688613) has shown a significant increase, closing at 25.41 yuan on February 10, 2026, with a rise of 5.13% and notable trading activity [1] Group 1: Stock Performance - On February 10, 2026, Aojing Medical's stock price increased by 5.13%, with a trading volume of 115,800 shares and a total transaction value of 289 million yuan [1] - The stock's turnover rate was 8.45%, indicating active trading [1] Group 2: Capital Flow - On February 10, 2026, the net inflow of main funds was 16.23 million yuan, accounting for 5.62% of the total transaction value, while retail investors experienced a net outflow of 25.61 million yuan, representing 8.87% of the total [1][2] - Over the past five days, the stock has seen fluctuating capital flows, with the highest net inflow of main funds recorded on February 9, 2026, at 2.45 million yuan [2] Group 3: Financing and Margin Trading - On February 10, 2026, the financing buy-in was 47.74 million yuan, with a net financing purchase of 9.29 million yuan, marking a cumulative net purchase of 13.24 million yuan over three consecutive days [2][3] - The margin trading balance stood at 235 million yuan, with a short selling volume of 4,771 shares and a remaining short selling balance of 38,300 yuan [3] Group 4: Company Financials and Industry Comparison - Aojing Medical reported a total market value of 3.481 billion yuan, with a net profit of 13.94 million yuan, reflecting a year-on-year increase of 185.19% [5] - The company's gross profit margin is 68.9%, significantly higher than the industry average of 50.61%, ranking 25th in the industry [5] - The company's return on equity (ROE) is 0.98%, which is above the industry average of 0.52%, ranking 89th in the industry [5]

Core Insights - Suzhou Municipal Bureau of Commerce has released the "Suzhou 2026 Trade Promotion Plan" to support local foreign trade enterprises in expanding their markets and diversifying their market structures [1][2] Group 1: Trade Promotion Plan Overview - The plan recommends a total of 586 domestic and international exhibitions, with 564 being overseas exhibitions, including 200 key recommended exhibitions and 364 general recommendations [1] - The geographical coverage of the exhibitions has expanded to 58 countries and regions, an increase of 7 compared to 2025 [1] - The plan emphasizes the importance of emerging markets, recommending 350 exhibitions in regions such as Southeast Asia, Central and Eastern Europe, South America, and Africa, which accounts for over 62% of the total recommended exhibitions [1] Group 2: Industry Focus and Exhibition Quality - The 2026 trade promotion plan includes 471 overseas exhibitions focused on goods trade (including 3 international cooperation exhibitions) and 93 service trade exhibitions [2] - The recommended exhibitions highlight key industries such as textiles, home appliances, hardware tools, machinery, and medical devices, while also promoting emerging fields like artificial intelligence, low-altitude economy, and green energy [2] - The number of recommended overseas exhibitions has increased by 231 compared to 2025, with a focus on selecting high-impact exhibitions based on previous participation by Suzhou enterprises [2]

Core Viewpoint - Southbound funds have reduced their holdings in Spring Medical (01858.HK) by 31,000 shares on February 10, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings on 4 days, with a total net reduction of 789,500 shares [1] - Over the past 20 trading days, there have been 11 days of net selling, resulting in a cumulative net reduction of 901,200 shares [1] - Currently, southbound funds hold 41,446,300 shares of Spring Medical, accounting for 43.55% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover major human joints such as hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Southbound funds have reduced their holdings in Gaoshi Medical (02407.HK) significantly over recent trading days, indicating a potential shift in investor sentiment towards the company [1]. Group 1: Shareholding Changes - On February 10, 2026, southbound funds reduced their holdings by 11,600 shares, bringing the total to 5,669,700 shares, which represents a decrease of 0.20% [2]. - Over the past five trading days, there has been a cumulative net reduction of 48,500 shares, with reductions occurring on all five days [1]. - In the last twenty trading days, the total net reduction reached 197,000 shares, with reductions on all twenty days [1]. Group 2: Company Overview - Gaoshi Medical Technology Co., Ltd. is primarily engaged in the research, development, manufacturing, and sales of ophthalmic medical devices and consumables [2]. - The company operates four segments: proprietary products, distribution, technical services, and other services, including clinical research organization services [2].

Core Viewpoint - The announcement details the unlocking and listing of restricted stocks under the 2021 stock incentive plan of Shandong Xinhua Medical Instrument Co., Ltd, with 2,282,513 shares set to be released on February 24, 2026 [2][4][18]. Group 1: Stock Incentive Plan Overview - The stock type being listed is part of the stock incentive plan, with a total of 2,282,513 shares to be unlocked [2][3]. - The third phase of the restricted stock under the 2021 incentive plan is being unlocked, with the unlocking date set for February 24, 2026 [4][16]. Group 2: Approval and Implementation Process - The stock incentive plan was approved during the board meeting on November 24, 2021, with independent directors providing their opinions [5][6]. - The plan underwent necessary public disclosures and received approvals from relevant authorities, including the State-owned Assets Management Unit [8][9]. Group 3: Unlocking Conditions and Details - The unlocking conditions for the third phase have been met, as confirmed by the board, allowing 324 eligible participants to unlock a total of 2,282,513 shares, which represents approximately 0.38% of the company's total share capital [17][20]. - The specific conditions for unlocking include performance metrics that align with the company's strategic goals [16]. Group 4: Stock Listing and Transfer Restrictions - The shares will be listed for trading on February 24, 2026, with specific transfer restrictions for directors and senior management during their tenure and for six months post-departure [18][19]. - The company will retain rights to any profits made from shares sold within six months of purchase or sale by directors and senior management [18]. Group 5: Independent Opinions and Legal Compliance - Independent directors have expressed that the unlocking process complies with relevant regulations and does not harm the interests of the company or its shareholders [20]. - Legal opinions confirm that all necessary approvals and procedures have been followed for the unlocking of shares [21].

经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；第一类医疗器械生产； 第一类医疗器械销售；第二类医疗器械销售；非居住房地产租赁；货物进出口；技术进出口。（除依法 须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目：第二类医疗器械生产；第三类医疗 器械生产；第三类医疗器械经营。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体 经营项目以相关部门批准文件或许可证件为准） 企业名称上海泰硕医疗技术有限公司法定代表人赵文涛注册资本3000万人民币国标行业科学研究和技术 服务业>专业技术服务业>工业与专业设计及其他专业技术服务地址上海市闵行区方亭路499号10幢11层 1121室企业类型有限责任公司（非自然人投资或控股的法人独资）营业期限2026-2-10至无固定期限登 记机关闵行区市场监督管理局 来源：市场资讯 天眼查显示，近日，上海泰硕医疗技术有限公司成立，法定代表人为赵文涛，注册资本3000万人民币， 由上海泰硕医疗科技有限公司全资持股。 序号股东名称持股比例1上海泰硕医疗科技有限公司100% ...

Core Viewpoint - The company is actively pursuing international expansion and product innovation while addressing currency fluctuations and market competition challenges. Group 1: Stock Performance and Market Activity - As of February 10, 2026, the company's stock closed at 190.36 yuan, with a slight increase of 0.63% and a trading volume of 51,700 shares, resulting in a transaction value of 983 million yuan [1] - On February 10, 2026, there was a net inflow of 45.8035 million yuan from main funds, indicating significant buying interest [10] Group 2: International Listing and Regulatory Approvals - The company submitted an application for H-share listing on the Hong Kong Stock Exchange on November 10, 2025, which is pending approval from various regulatory bodies [2] Group 3: Currency Impact on Financial Performance - Approximately 50% of the company's sales revenue comes from overseas, primarily settled in USD and EUR, making it susceptible to fluctuations in the RMB exchange rate, which can affect revenue and profit margins [3] - The company is implementing strategies such as foreign exchange hedging and fixed-rate agreements to mitigate the impact of currency fluctuations on its business operations [3] Group 4: Product and Market Positioning - The company has established a strong global network in R&D, manufacturing, marketing, and service, with its six major product lines ranking among the top three in global markets [4] - As of June 30, 2025, the company's products were sold in over 190 countries, with overseas revenue accounting for approximately 45% of total revenue in 2024 [4] - In the European and American markets, the company achieved over 5.5 billion yuan in revenue in 2024, representing 15% of total revenue, highlighting its brand strength and sales growth [4] Group 5: AI and Innovation Strategy - The company emphasizes its commitment to medical AI, with applications in critical care and various clinical scenarios, although it faces challenges in market perception and growth potential [5] - There is a call for the company to enhance its corporate culture and innovation focus to bridge the gap with international competitors and improve product pricing power [6] Group 6: Shareholder Engagement and Future Plans - As of September 30, 2025, the total number of shareholders was 108,835 [7] - The company plans to release its annual report for 2025 on March 31, 2026, which will provide insights into its financial performance [8]

Core Viewpoint - The article discusses the IPO application of Tangji Medical Technology Co., Ltd., which focuses on the development and commercialization of medical devices related to metabolic diseases, particularly obesity and type 2 diabetes [4][5]. Market and Industry Overview - Tangji Medical operates in the healthcare sector related to metabolic diseases, which includes obesity, overweight, type 2 diabetes, and metabolic-associated fatty liver disease (MASH). These chronic diseases pose a significant burden on global healthcare systems, with approximately 6.7 million deaths related to diabetes globally in 2021, including about 1.4 million in China. The corresponding medical expenditures were $966 billion globally and $165 billion in China [5]. - The demand for medical solutions addressing metabolic diseases is expected to grow due to aging populations, lifestyle changes, and increased disease screening rates, providing substantial market opportunities for medical devices [5]. Company Development and Product Introduction - Established in 2016, Tangji Medical has focused on the research and industrialization of medical devices, expanding its presence in both domestic and international markets. The company operates through multiple subsidiaries, including Jikang Medical in Quzhou and Tangji Health Technology in Tianjin, and has established overseas entities in Hong Kong and Singapore [8]. - The product portfolio includes a gastric bypass stent system that reduces sugar and fat absorption and stimulates GLP-1 secretion to lower blood sugar and aid weight loss. This product has received approval from the Chinese National Medical Products Administration and is recognized as a "breakthrough device" by the FDA in the U.S. Additionally, the company has launched a digital health management software for obesity, which is the first of its kind to receive medical device registration in China [8]. Financial Status and Stage Assessment - Tangji Medical is currently not profitable, primarily due to high R&D expenditures and ongoing investments in industrialization and market expansion. The company has accumulated a certain scale of tax losses in China. Similar to other early-stage medical device companies, Tangji Medical is still in the process of accumulating R&D results and market presence [9]. - The company aims to build a product system focused on chronic and metabolic disease needs, indicating a long-term strategy rather than a short-term performance-driven IPO case. The market potential remains strong due to the rising burden of metabolic diseases, but the company's success will depend on the registration progress, commercialization capabilities, and clinical application of its core products [9]. Market Outlook - The market for Tangji Medical is expected to grow significantly due to the increasing prevalence of obesity and metabolic diseases. The company's advancements in R&D and clinical applications, particularly the approval of the gastric bypass stent system and the expansion into digital health management, are likely to enhance its market share [10]. - The IPO of Tangji Medical is attracting considerable attention in the medical device sector, especially in the weight loss and metabolic disease fields. As products gradually enter the market, the company is positioned to become a leading player in this domain [10].

Core Viewpoint - The successful completion of the first robot-assisted percutaneous coronary intervention (PCI) at Beijing Friendship Hospital's Shunyi District marks a significant advancement in the field of cardiovascular intervention and showcases the hospital's leadership in smart medical technology [2][7]. Group 1: Procedure Details - A 65-year-old male patient diagnosed with coronary heart disease and unstable angina underwent the procedure, which involved severe stenosis in the circumflex artery and was completed in just 20 minutes [2][4]. - The procedure utilized a vascular intervention control system, allowing for remote operation and precise control during the stent placement, resulting in the complete resolution of the stenosis [4][5]. Group 2: Technological Innovation - The vascular intervention control system, developed by a startup incubated by the Chinese Academy of Sciences, is the first of its kind in China to provide multi-channel assistance throughout the procedure, significantly enhancing safety and precision [8][9]. - This system allows operators to perform procedures from a shielded control room, avoiding X-ray exposure, and improves operational comfort and decision-making during surgery [8][9]. Group 3: Clinical and Industry Impact - The successful implementation of this technology not only offers safer and more precise treatment options for cardiovascular patients but also promotes the innovation and clinical application of high-end medical devices in China [9]. - The hospital aims to continue enhancing patient-centered services and accelerate the translation of medical-engineering collaborative results to contribute to the health of the nation [9].